What did Crown Laboratories, Inc. pay for Revance Therapeutics, Inc.?

Crown Laboratories, Inc. acquired Revance Therapeutics, Inc. for $924.0M in 2024, equivalent to 3.70x revenue. Target revenue was approximately $251.2M.

What does Revance Therapeutics, Inc. do?

Revance Therapeutics, Inc. is a medical devices business.

What multiple did Crown Laboratories, Inc. pay for Revance Therapeutics, Inc.?

3.70x revenue, based on disclosed deal value of $924.0M and disclosed financials.

M&A TRANSACTION · 2024

Revance Therapeutics, Inc. acquired by Crown Laboratories, Inc.

$924.0M· 3.70x revenue

Target

Revance Therapeutics, Inc.

Acquirer

Crown Laboratories, Inc.

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$251.2M

EBITDA

—

Deal Value

$924.0M

EV/EBITDA

—

Context

This $924.0M acquisition of Revance Therapeutics, Inc. by Crown Laboratories, Inc. sits in the medical devices sub-vertical. Crown Laboratories, Inc. is acquiring as a strategic buyer; see how strategic acquirers typically price medical devices businesses on our Medical Devices strategic buyer-pool page.

Source

Data sourced from Press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Revance Therapeutics, Inc. acquisition.

Citation: ExitValue.ai. (2024). Revance Therapeutics, Inc. acquired by Crown Laboratories, Inc.. https://exitvalue.ai/deals/revance-therapeutics-inc-acquired-by-crown-laboratories-inc-hc-2024-0025